Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hong-Hong Yan

Showing results (81-90 of 118) with videos related to

Pageof 12
Sort By:
Lung Cancer (Amsterdam, Netherlands)|October 20, 2012
Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancerJin-Ji Yang, Hua-Jun Chen, Hong-Hong Yan, et al.
Clinical Lung Cancer|June 6, 2022
Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non-Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG1705)Si-Yang Maggie Liu, Hong-Hong Yan, Xue-Wu Wei, et al.
Lung Cancer (Amsterdam, Netherlands)|October 30, 2020
Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improve post-progression survivals: A single-center retrospective studyJiang-Tao Cheng, Yi-Hui Yao, Yu-Er Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2025
Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non-Small Cell Lung CancerJia-Tao Zhang, Si-Yang Liu, Xuan Gao, et al.
JTO Clinical and Research Reports|January 6, 2025
Monitoring of Circulating Tumor DNA and Indication of De-Escalation Adjuvant Targeted Therapy for <i>EGFR</i>-Mutated NSCLC After Complete ResectionSong Dong, Bingfa Yan, Si-Yang Liu, et al.
Lung Cancer (Amsterdam, Netherlands)|December 6, 2022
A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survivalChan-Yuan Zhang, Hao Sun, Jun-Wei Su, et al.
Journal of Thoracic Disease|October 23, 2023
Expression of <i>EGFR</i>-mutant proteins and genomic evolution in <i>EGFR</i>-mutant transformed small cell lung cancerShi-Ling Zhang, Chan-Yuan Zhang, Yu-Qing Chen, et al.
Lung Cancer (Amsterdam, Netherlands)|March 31, 2026
Adjuvant immunotherapy may have no impact on survival in patients who received neoadjuvant immunotherapy for stage II-IIIB non-small cell lung cancerJun-Tao Lin, Xue-Ning Yang, Xiang-Meng Li, et al.
Oncotarget|August 18, 2016
Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterationsNa-Na Lou, Xu-Chao Zhang, Hua-Jun Chen, et al.
Thoracic Cancer|July 8, 2020
Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patientsJing-Hua Chen, Xiang-Peng Chu, Jia-Tao Zhang, et al.
Pageof 12

Showing results (81-90 of 118) with videos related to

Sort By:
Pageof 12
Lung Cancer (Amsterdam, Netherlands)|October 20, 2012
Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancerJin-Ji Yang, Hua-Jun Chen, Hong-Hong Yan, et al.
Clinical Lung Cancer|June 6, 2022
Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non-Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG1705)Si-Yang Maggie Liu, Hong-Hong Yan, Xue-Wu Wei, et al.
Lung Cancer (Amsterdam, Netherlands)|October 30, 2020
Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improve post-progression survivals: A single-center retrospective studyJiang-Tao Cheng, Yi-Hui Yao, Yu-Er Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2025
Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non-Small Cell Lung CancerJia-Tao Zhang, Si-Yang Liu, Xuan Gao, et al.
JTO Clinical and Research Reports|January 6, 2025
Monitoring of Circulating Tumor DNA and Indication of De-Escalation Adjuvant Targeted Therapy for <i>EGFR</i>-Mutated NSCLC After Complete ResectionSong Dong, Bingfa Yan, Si-Yang Liu, et al.
Lung Cancer (Amsterdam, Netherlands)|December 6, 2022
A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survivalChan-Yuan Zhang, Hao Sun, Jun-Wei Su, et al.
Journal of Thoracic Disease|October 23, 2023
Expression of <i>EGFR</i>-mutant proteins and genomic evolution in <i>EGFR</i>-mutant transformed small cell lung cancerShi-Ling Zhang, Chan-Yuan Zhang, Yu-Qing Chen, et al.
Lung Cancer (Amsterdam, Netherlands)|March 31, 2026
Adjuvant immunotherapy may have no impact on survival in patients who received neoadjuvant immunotherapy for stage II-IIIB non-small cell lung cancerJun-Tao Lin, Xue-Ning Yang, Xiang-Meng Li, et al.
Oncotarget|August 18, 2016
Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterationsNa-Na Lou, Xu-Chao Zhang, Hua-Jun Chen, et al.
Thoracic Cancer|July 8, 2020
Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patientsJing-Hua Chen, Xiang-Peng Chu, Jia-Tao Zhang, et al.
Pageof 12